GlassScriptPhysician profile
Joseph Daniel Davis
NPI 1548268295
$16,681.13
in general payments reported to CMS, 2019-2025
49 companies · $3,366 in 2025
The $3,366 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $992 · 2021: $1,562 · 2022: $2,402 · 2023: $4,063 · 2024: $3,011 · 2025: $3,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,309.82 |
| Education | $129.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,176.64 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Janssen Biotech, INC. | $1,847.19 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,585.47 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,561.22 | 2019-2025 | Entyvio, Eohilia, Vpriv |
| Pfizer INC. | $977.17 | 2021-2025 | |
| Celgene Corporation | $972.58 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $715.24 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $585.97 | 2020-2025 | Rebyota, Cimzia, Clenpiq |
| Ardelyx, INC. | $437.36 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $362.96 | 2022-2025 | Dupixent |
| Genzyme Corporation | $325.74 | 2022-2025 | |
| Gilead Sciences, INC. | $321.32 | 2019-2025 | Livdelzi |
| Lilly USA, LLC | $282.22 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $267.64 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $226.07 | 2020-2024 | Linzess |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $224.41 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $184.59 | 2020-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $173.97 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $142.00 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $122.74 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $114.84 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $113.38 | 2022-2025 | Injectafer |
| Medtronic, INC. | $110.41 | 2021-2023 | Pillcam, Interstim |
| Allergan, INC. | $101.42 | 2019-2020 | |
| Olympus America INC. | $79.31 | 2021-2022 | |
| Ucb, INC. | $74.60 | 2019-2020 | |
| Novo Nordisk INC | $67.12 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $60.18 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $51.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.06 | 2023-2024 | Cyltezo |
| Orphalan INC | $32.32 | 2025 | Cuvrior |
| Intra-Sana Laboratories | $31.37 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Braintree Laboratories, INC. | $30.44 | 2022 | |
| Evoke Pharma, INC. | $30.31 | 2024-2025 | |
| Shionogi INC | $30.13 | 2019 | |
| W. L. Gore & Associates, INC. | $28.05 | 2022-2023 | Gore Cardioform Septal Occluder |
| Biosense Webster, INC. | $28.02 | 2023 | Carto 3 |
| Fresenius Kabi USA, LLC | $26.00 | 2023 | Idacio |
| Intuitive Surgical, INC. | $23.33 | 2023 | |
| Alfasigma USA, INC. | $23.02 | 2020 | |
| Celltrion USA INC. | $21.46 | 2024 | Zymfentra |
| Boston Scientific Corporation | $19.08 | 2022 | |
| Echosens North America, INC. | $19.07 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.91 | 2025 | Monoferric |
| Exact Sciences Corporation | $14.74 | 2025 | Cologuard Collection Kit |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.